Humacyte Q3 2023 Earnings Report $3.04 -0.17 (-5.16%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Humacyte EPS ResultsActual EPS-$0.25Consensus EPS -$0.25Beat/MissMet ExpectationsOne Year Ago EPSN/AHumacyte Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHumacyte Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call ResourcesPress ReleaseHUMA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Humacyte Earnings HeadlinesHumacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025March 3 at 8:00 AM | globenewswire.comHumacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral CapitalFebruary 28, 2025 | americanbankingnews.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.March 5, 2025 | Chaikin Analytics (Ad)Humacyte to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comHumacyte shares rise after patent for bioengineered human tissues manufacturingFebruary 27, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF) and Humacyte (HUMA)February 27, 2025 | markets.businessinsider.comSee More Humacyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email. Email Address About HumacyteHumacyte (NASDAQ:HUMA) engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.View Humacyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Broadcom (3/6/2025)Costco Wholesale (3/6/2025)JD.com (3/6/2025)Canadian Natural Resources (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
